BACKGROUND. Creutzfeldt-Jakob disease is a transmissible neurodegenerative disorder that occurs more than 100 times more frequently among Libyan Jews than in the worldwide population. We examined 11 patients with the disease--10 Libyan Jews from Israel and 1 Libyan Jew from Italy--to determine whether abnormalities of the prion protein could be detected in them. Abnormal forms of this host-encoded protein are the predominant if not sole components of the transmissible agent that causes the disease. METHODS. The prion-protein open-reading frame in peripheral-leukocyte DNA from the Italian patient was amplified with the polymerase chain reaction and sequenced. Allele-specific oligonucleotide hybridization was used to assess a prion-protein codon 200 lysine mutation in the 10 Israeli patients and 37 control subjects. RESULTS. The prion-protein sequence in DNA from the Italian patient revealed a single nucleotide change (G----A) at the first position of codon 200 that resulted in a substitution of lysine for glutamate. This substitution was detected in all 10 Israeli patients, 8 of whom had a positive family history of Creutzfeldt-Jakob disease. One patient was homozygous for the lysine mutation, and her clinical course did not differ from that of the patients heterozygous for the mutation. The lysine mutation was not found in one Moroccan Jew from Israel with Creutzfeldt-Jakob disease. CONCLUSIONS. The codon 200 lysine mutation of the prion-protein gene is consistently present among Libyan Jews with Creutzfeldt-Jakob disease, strongly supporting a genetic pathogenesis of their illness. The similarity of the clinical courses of the patient homozygous for this mutation and the patients heterozygous for it argues that familial Creutzfeldt-Jakob disease is a true dominant disorder.
Source Information
Department of Neurology, University of California, San Francisco.
This article has been cited by other articles:
Fulbright, R.K., Hoffmann, C., Lee, H., Pozamantir, A., Chapman, J., Prohovnik, I.
(2008). MR Imaging of Familial Creutzfeldt-Jakob Disease: A Blinded and Controlled Study. Am. J. Neuroradiol.
29: 1638-1643
[Abstract][Full Text]
Haviv, Y., Avrahami, D., Ovadia, H., Ben-Hur, T., Gabizon, R., Sharon, R.
(2008). Induced Neuroprotection Independently From PrPSc Accumulation in a Mouse Model for Prion Disease Treated With Simvastatin. Arch Neurol
65: 762-775
[Abstract][Full Text]
Peden, A. H., Ritchie, D. L., Head, M. W., Ironside, J. W.
(2006). Detection and Localization of PrPSc in the Skeletal Muscle of Patients with Variant, Iatrogenic, and Sporadic Forms of Creutzfeldt-Jakob Disease. Am. J. Pathol.
168: 927-935
[Abstract][Full Text]
Scott, M. R., Peretz, D., Nguyen, H.-O. B., DeArmond, S. J., Prusiner, S. B.
(2005). Transmission Barriers for Bovine, Ovine, and Human Prions in Transgenic Mice. J. Virol.
79: 5259-5271
[Abstract][Full Text]
Atarashi, R., Nishida, N., Shigematsu, K., Goto, S., Kondo, T., Sakaguchi, S., Katamine, S.
(2003). Deletion of N-terminal Residues 23-88 from Prion Protein (PrP) Abrogates the Potential to Rescue PrP-deficient Mice from PrP-like Protein/Doppel-induced Neurodegeneration. J. Biol. Chem.
278: 28944-28949
[Abstract][Full Text]
Rentz, C. A.
(2003). Creutzfeldt-Jakob disease: Two case studies. AM J ALZHEIMERS DIS OTHER DEMEN
18: 171-180
[Abstract]
Ben-Zeev, B., Gross, V., Kushnir, T., Shalev, R., Hoffman, C., Shinar, Y., Pras, E., Brand, N.
(2001). Vacuolating Megalencephalic Leukoencephalopathy in 12 Israeli Patients. J Child Neurol
16: 93-99
[Abstract]
Supattapone, S., Nguyen, H.-O. B., Muramoto, T., Cohen, F. E., DeArmond, S. J., Prusiner, S. B., Scott, M.
(2000). Affinity-Tagged Miniprion Derivatives Spontaneously Adopt Protease-Resistant Conformations. J. Virol.
74: 11928-11934
[Abstract][Full Text]
Hillier, C. E. M., Salmon, R. L.
(2000). Is there evidence for exogenous risk factors in the aetiology and spread of Creutzfeldt-Jakob disease?. QJM
93: 617-631
[Full Text]
Capellari, S., Parchi, P., Russo, C. M., Sanford, J., Sy, M.-S., Gambetti, P., Petersen, R. B.
(2000). Effect of the E200K Mutation on Prion Protein Metabolism : Comparative Study of a Cell Model and Human Brain. Am. J. Pathol.
157: 613-622
[Abstract][Full Text]
Rosenmann, H., Kahana, E., Korczyn, A. D., Kahana, I., Chapman, J., Gabizon, R.
(1999). Preliminary evidence for anticipation in genetic E200K Creutzfeldt-Jakob disease. Neurology
53: 1328-1328
[Abstract][Full Text]
Prusiner, S. B.
(1998). Prions. Proc. Natl. Acad. Sci. USA
95: 13363-13383
[Abstract][Full Text]
Scott, M. R., Safar, J., Telling, G., Nguyen, O., Groth, D., Torchia, M., Koehler, R., Tremblay, P., Walther, D., Cohen, F. E., DeArmond, S. J., Prusiner, S. B.
(1997). Identification of a prion protein epitope modulating transmission of bovine spongiform encephalopathy prions to transgenic mice. Proc. Natl. Acad. Sci. USA
94: 14279-14284
[Abstract][Full Text]
Prusiner, S. B.
(1997). Prion Diseases and the BSE Crisis. Science
278: 245-251
[Abstract][Full Text]
Lehmann, S., Harris, D. A.
(1996). Mutant and Infectious Prion Proteins Display Common Biochemical Properties in Cultured Cells. J. Biol. Chem.
271: 1633-1637
[Abstract][Full Text]
Prusiner, S.
(1991). Molecular biology of prion diseases. Science
252: 1515-1522
[Abstract]
Shaked, G. M., Shaked, Y., Kariv-Inbal, Z., Halimi, M., Avraham, I., Gabizon, R.
(2001). A Protease-resistant Prion Protein Isoform Is Present in Urine of Animals and Humans Affected with Prion Diseases. J. Biol. Chem.
276: 31479-31482
[Abstract][Full Text]
Previous
